Hit enter to search or ESC to close
The Central Bank of Nigeria (CBN), as part of its policy response to the COVID-19 pandemic, introduces the Healthcare Sector Research and Development Intervention Scheme (HSRDIS) to help strengthen the public healthcare system with innovative financing of research and development (R&D) in new and improved drugs, vaccines and diagnostics of infectious diseases in Nigeria.
Specifically, the HSRDIS is designed to trigger intense national R&D activities to develop a Nigerian vaccine, drugs and herbal medicines against the spread of COVID-19 and any other communicable or non-communicable diseases through the provision of grants to biotechnological and pharmaceutical companies, institutions, researchers, and research institutes for the research and development of drugs, herbal medicines and vaccines for the control, prevention and treatment of infectious diseases.
The Scheme is intended to boost domestic manufacturing of critical drugs and vaccines to ensure their sustainable domestic supply and reduce the bulk manufacturing costs of the drugs, herbal medicines and vaccines in Nigeria.
The broad objectives of Scheme include is to provide grants for R&D in new or revalidation of drug molecule,
phytomedicines and vaccines for the control, prevention and treatment of infectious diseases in Nigeria; Boosting domestic manufacturing of validated drugs (Active Pharmaceutical Ingredients or APIs), herbal medicines and vaccines for the control, prevention and treatment of infectious diseases in Nigeria and reduce the nation’s dependence on other countries for these drugs and vaccines.
Also, the objective of this CBN grant is to improve the capacity of the biotechnological and pharmaceutical companies, institutions, researchers, and research institutes in the development of approved Nigerian drugs, herbal medicines and vaccines for infectious diseases.
To support capacity of relevant health agencies towards attaining World Health Organization (WHO) Maturity Level 3, a prerequisite for manufacturing of vaccines in Nigeria; and to Facilitate partnership between academia (researchers, research institutes and universities) and industry into the research and development of drugs, phytomedicines and vaccines for the control, prevention and treatment of infectious diseases in Nigeria.
FAKE DIESEL IN CIRCULATION
Lastly, to reduce dependence on imported drug products (synthetic and herbal) and vaccines for the control, prevention and treatment of infectious diseases in Nigeria.
Eligible Research and Development Activities
NOTE: Candidate vaccines undergoing pre-clinical testing or trials shall not be eligible for consideration under this Scheme. However, candidate vaccines undergoing clinical testing or trials shall be eligible for consideration under the Scheme if considered to have high potential to cross the clinical trial stage and prospects of scale by the Body of Experts (BoE).
In applying for this CBN grant, the applicant shall be required to have conducted pre- clinical testing of the candidate drugs, herbal medicines and vaccines, and obtained certification from relevant health authorities for further research and development.
Special consideration shall be given to candidate drugs, herbal medicines and vaccines with high scientific merit against emerging infections and contribute to the development of the Nigerian vaccine.
For this purpose, a BoE shall be constituted from the academia and industry to review validated research proposal submitted and recommend for financing, as appropriate. The BoE shall meet regularly to appraise the research and development project and submit progress reports to the CBN.
The Scheme for this CBN grant shall be funded from the Developmental Component of the Micro, Small and Medium Enterprise Development Fund (MSMEDF).
NOTE: Disbursement under the Scheme shall be made to beneficiaries in tranches subject to approved milestones achieved.
LISTEN TO OUR LATEST PODCAST: SHOW ME YOUR FRIEND
Research and Development Time-frame
Body of Experts
The Body of Experts (BoE) shall be responsible for the review and evaluation of submitted research proposals, as well as recommend for financing R&D projects with high potential to contribute to the development of the Nigerian vaccines for infectious diseases. The composition of the BoE shall be as detailed below:
NOTE: The Chair of the BoE shall be appointed by the CBN.
METHOD OF APPLICATION
NOTE: The CBN shall have proprietary right over all financed R&D outcomes or products. Equally, licensing protocol for the mass manufacturing of developed drugs, phytomedicines and vaccines shall be defined by the BoE in accordance with the World Health Organization’s current Good Manufacturing Practices (cGMP).
Periodic joint monitoring of research and development activities shall be conducted by the BoE. The Framework shall be subject to review from time to time as may be deemed necessary by the CBN. More details can be found HERE!
Enquiries and Returns
All inquiries and returns should be addressed to:
Development Finance Department,
Central Bank of Nigeria,
About the author
This site uses Akismet to reduce spam. Learn how your comment data is processed.